KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardlytics (CDLX) Operating Expenses (2017 - 2025)

Cardlytics (CDLX) has disclosed Operating Expenses for 9 consecutive years, with $62.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Expenses fell 24.45% year-over-year to $62.2 million, compared with a TTM value of $335.1 million through Dec 2025, down 29.28%, and an annual FY2025 reading of $335.1 million, down 29.28% over the prior year.
  • Operating Expenses was $62.2 million for Q4 2025 at Cardlytics, down from $120.9 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $465.1 million in Q4 2022 and bottomed at $32.3 million in Q1 2022.
  • Average Operating Expenses over 5 years is $119.9 million, with a median of $95.0 million recorded in 2023.
  • The sharpest move saw Operating Expenses surged 336.92% in 2022, then tumbled 58.7% in 2023.
  • Year by year, Operating Expenses stood at $106.5 million in 2021, then soared by 336.92% to $465.1 million in 2022, then crashed by 58.7% to $192.1 million in 2023, then plummeted by 57.15% to $82.3 million in 2024, then dropped by 24.45% to $62.2 million in 2025.
  • Business Quant data shows Operating Expenses for CDLX at $62.2 million in Q4 2025, $120.9 million in Q3 2025, and $76.0 million in Q2 2025.